Swayampakula Ramakanth analyst

Currently out of the existing stock ratings of Swayampakula Ramakanth, 295 are a BUY (94.25%), 18 are a HOLD (5.75%).

Swayampakula Ramakanth

Work Performance Price Targets & Ratings Chart

Analyst Swayampakula Ramakanth, currently employed carries an average stock price target met ratio of 29.73% that have a potential upside of 46.54% achieved within 152 days. Previously, Swayampakula Ramakanth worked at HC WAINWRIGHT.

Swayampakula Ramakanth’s has documented 577 price targets and ratings displayed on 54 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on INAB, In8bio  at 14-Jun-2024.

Wall Street Analyst Swayampakula Ramakanth

Analyst best performing recommendations are on ABSI (ABSCI CORP).
The best stock recommendation documented was for PGEN (PRECIGEN) at 12/16/2020. The price target of $10 was fulfilled within 6 days with a profit of $2.51 (33.51%) receiving and performance score of 55.85.

Average potential price target upside

EKSO Ekso Bionics Holdings PGEN Precigen TRIL Trillium Therapeutics VSTM Verastem BCAB Bioatla  BCYC Bicycle Therapeutics Ltd CALA Calithera Biosciences CDXS Codexis HARP Harpoon Therapeutics HOOK Hookipa Pharma ITOS Iteos Therapeutics  MDXG MiMedx Group OCGN Ocugen PLSE Pulse Biosciences DCTH Delcath Systems ECOR Electrocore LLC MDNA Medicenna Therapeutics Corp PSNL Personalis SURF Surface Oncology VOR Vor Biopharma XFOR X4 Pharmaceuticals CORT Corcept Therapeutics orporated MDWD Mediwound Ltd ONCR Oncorus  IMGN ImmunoGen AFMD Affimed NV ALXO Alx Oncology Holdings  ASXC Asensus Surgical CELU Celularity EDAP EDAP TMS SA INAB In8bio  IPA Immunoprecise Antibodies Ltd LPTX Leap Therapeutics RWLK Rewalk Robotics Ltd SRGA Surgalign Holdings VCEL Vericel Corp Ord ABSI Absci Corp AVGR Avinger IPHA Innate Pharma JANX Janux Therapeutics TCRT Alaunos Therapeutics ATEC Alphatec Holdings AVEO AVEO Pharmaceuticals CASI CASI Pharmaceuticals CLRB Cellectar Biosciences PSTI Pluristem QSI QuantumSi JNCE Jounce Therapeutics KIN Kindred Biosciences SESN Sesen Bio TARA Protara Therapeutics MESO Mesoblast Ltd VBLT Vascular Biogenics Ltd EVAX Evaxion Biotech AS

Analyst name


Current price target

Potential Upside

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$8.81 (740.34%)


2 months 18 days ago

1/4 (25%)

$8.75 (700.00%)


Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Swayampakula Ramakanth is most bullish on?

Potential upside of $32.34 has been obtained for BCYC (BICYCLE THERAPEUTICS LTD)

Which stock is Swayampakula Ramakanth is most reserved on?

Potential downside of $2.93 has been obtained for QSI (QUANTUMSI)

What Year was the first public recommendation made by Swayampakula Ramakanth?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?